OPM-101 + pembrolizumab

OPM-101 + pembrolizumab is an investigational combination therapy currently in clinical trials for **patients with advanced or metastatic melanoma who have developed resistance to prior anti-PD-1 therapy**. - **OPM-101** is a selective small molecule inhibitor of RIPK2 (Receptor-interacting serine/threonine-protein kinase 2), administered orally, which demonstrates immunomodulatory activity by inhibiting the pro-inflammatory RIPK2 pathway and reducing TNFα production. - **Pembrolizumab (Keytruda)** is an authorized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, administered intravenously, functioning as an immune checkpoint inhibitor to promote antitumor immune responses. Preclinical and early clinical data show that OPM-101 can enhance tumor antigen presentation, remodel CD8+ T cell infiltration, and potentially resensitize tumors to PD-1 blockade when used with pembrolizumab, enabling responses in melanoma patients whose disease has become resistant to anti-PD-1 therapy[1][3][5][7].

Other names

OPM-101 + Keytruda